This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. CALT, ZYME, SBTX, MBX, AVTE, NLTX, BIOA, CYBN, VIRI, and WHWKShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Aquinox Pharmaceuticals vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Do institutionals & insiders hold more shares of CALT or AQXP? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CALT or AQXP more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Aquinox Pharmaceuticals N/A -30.13%-28.08% Which has more volatility and risk, CALT or AQXP? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, indicating that its share price is 837% less volatile than the S&P 500. Does the media prefer CALT or AQXP? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Aquinox Pharmaceuticals'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Aquinox Pharmaceuticals Neutral Which has better earnings & valuation, CALT or AQXP? Aquinox Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Aquinox Pharmaceuticals$25M18.81-$31.58MN/AN/A SummaryAquinox Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 6 of the 9 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$470.33M$850.26M$5.74B$9.75BDividend YieldN/A4.84%4.40%4.08%P/E RatioN/A1.1530.4126.03Price / Sales18.8126.24429.29104.41Price / CashN/A19.5625.7828.79Price / Book6.476.769.646.06Net Income-$31.58M-$4.17M$3.27B$265.83M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$19.98-0.1%N/A-42.8%$470.33M$25M0.008CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.3636 of 5 stars$14.10+0.4%$21.43+52.0%+27.9%$1.06B$122.87M-9.40460SBTXSilverback TherapeuticsN/A$14.03-3.4%N/A+4.2%$505.89MN/A-5.8083Positive NewsHigh Trading VolumeMBXMBX Biosciences1.923 of 5 stars$13.32-8.6%$37.63+182.5%N/A$447.47MN/A-2.9336News CoverageAVTEAerovate TherapeuticsN/A$7.50+1.9%N/A-87.4%$217.39MN/A-2.5120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.45-0.3%N/A-42.8%$192.19MN/A-6.5890High Trading VolumeBIOABioAge LabsN/A$4.42-2.2%N/AN/A$158.46M$3.86M0.00N/ACYBNCybin2.3866 of 5 stars$6.59-4.8%$85.00+1,189.8%N/A$155.46MN/A-1.5050News CoverageGap UpVIRIVirios TherapeuticsN/A$5.30+7.5%$5.00-5.7%+2,250.8%$102.07MN/A-19.635Gap UpWHWKWhitehawk TherapeuticsN/A$1.65+2.5%N/AN/A$77.76M$25.98M-27.5040High Trading Volume Related Companies and Tools Related Companies CALT Competitors ZYME Competitors SBTX Competitors MBX Competitors AVTE Competitors NLTX Competitors BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access